SP-A Recombinant Rabbit mAb (SDT-3520-21)
SP-A Recombinant Rabbit mAb (SDT-3520-21)
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | SP-A |
| Synonyms | PSP-A; PSPA; SP-A; SP-A1 SP-A2; Pulmonary surfactant-associated protein A |
| Immunogen | Recombinant Protein |
| Clone Number | SDT-3520-21 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | Sandwich ELISA, CLIA |
| Reactivity | Hu |
| Cross Reactivity | Strong reactivity against both SP-A1 and SP-A2, no cross reactivity against SP-D. |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Purity | >95% by SEC-HPLC |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, 0.09% sodium azide |
| Stability & Storage | 12 months from date of receipt, 2 to 8 °C as supplied |
Background
Surfactant protein A (SP-A) is a lung-specific collectin and a promising noninvasive biomarker for various pulmonary disorders.
In idiopathic pulmonary fibrosis (IPF), serum SP-A levels are significantly elevated and reflect disease activity. With an optimal cut-off of 51.21 ng/mL, SP-A demonstrates a diagnostic sensitivity of 81.8% and specificity of 76.7% (AUC 0.858). Combining SP-A with other markers like KL-6, SP-D, and MMP-7 can further improve diagnostic accuracy. A recent meta-analysis of 2,573 interstitial lung disease (ILD) patients confirmed that elevated serum SP-A is a pivotal biomarker for assessing disease occurrence, progression, acute exacerbation, and mortality. Specifically, SP-A levels were significantly higher in progressive versus stable ILD, in acute exacerbation versus non-acute exacerbation, and in non-survivors versus survivors. In community-acquired pneumonia (CAP), lower serum SP-A on admission is associated with increased risks of mechanical ventilation, ICU admission, and poor prognosis. SP-A also shows diagnostic value in pulmonary alveolar proteinosis (PAP), tuberculosis, and as a marker for lung adenocarcinoma.
Overall, SP-A is a valuable diagnostic and prognostic biomarker, though standardization of assays and cut-off values remains a challenge for broader clinical translation.
Picture
Picture
Paired Recommendations
